Afficher la couverture 'Melflufen for the treatment of multiple myeloma | Ocio, Enrique' en grand format
/5

0 avis

Melflufen for the treatment of multiple myeloma

Archive ouverte

Ocio, Enrique | Nadeem, Omar | Schjesvold, Fredrik | Gay, Francesca | Touzeau, Cyrille | Dimopoulos, Meletios | Richardson, Paul | Mateos, Maria-Victoria

Edité par CCSD ; Informa Plc -

International audience. Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that takes advantage of increased aminopeptidase activity inside tumor cells to rapidly release alkylating agents therein. Melflufen in combination with dexamethasone has been evaluated in multiple clinical trials in patients with relapsed/refractory multiple myeloma (MM).

Consulter en ligne

Suggestions

Du même auteur

Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed/refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies.

Archive ouverte | Rodríguez-Otero, Paula | CCSD

International audience. 8048 Background: Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate (PDC) that leverages aminopeptidases and rapidly releases alkylating agents inside tumor cells. M...

Patient‐reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study

Archive ouverte | Larocca, Alessandra | CCSD

International audience. Relapsed/refractory multiple myeloma (RRMM) is known to have a high burden of disease and complications associated with refractoriness to prior lines of therapy. Severe pain and fatigue sympt...

Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage

Archive ouverte | Fernández de Larrea, Carlos | CCSD

International audience. Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment fo...

Chargement des enrichissements...